COSMO PHARMACEUTICALS NV (C43.DE) Stock Price, Quote, News and Overview
FRA:C43 - Deutsche Boerse Ag - NL0011832936 - Common Stock - Currency: EUR
C43.DE Quote, Performance and Key Statistics
FRA:C43 (3/7/2025, 7:00:00 PM)
57.5
-2 (-3.36%)
The current stock price of C43.DE is 57.5 EUR. In the past month the price decreased by -16.06%. In the past year, price decreased by -14.18%.
C43.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1LLY.MI | ELI LILLY & CO | 67 | 760.43B | ||
| LLY.DE | ELI LILLY & CO | 66.98 | 760.15B | ||
| ZEG.DE | ASTRAZENECA PLC | 21.82 | 446.45B | ||
| JNJ.DE | JOHNSON & JOHNSON | 16.81 | 372.31B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 16.61 | 367.98B | ||
| NOV.DE | NOVO NORDISK A/S-B | 26.21 | 355.97B | ||
| SNW.DE | SANOFI | 14.32 | 275.64B | ||
| SAN.PA | SANOFI | 14.27 | 274.84B | ||
| 1SAN.MI | SANOFI | 14.19 | 273.18B | ||
| 6MK.DE | MERCK & CO. INC. | 12.64 | 224.82B | ||
| 1MRKX.MI | MERCK & CO. INC. | 12.47 | 221.79B | ||
| PFE.DE | PFIZER INC | 8.69 | 140.81B |
Related stock screener links
About C43.DE
Company Profile
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. The company is headquartered in Dublin, Dublin and currently employs 339 full-time employees. The company went IPO on 2016-05-18. The firm is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
Company Info
COSMO PHARMACEUTICALS NV
Riverside II, Sir John Rogerson's Quay
DUBLIN DUBLIN IE
Employees: 339
Company Website: https://www.cosmopharma.com/
Investor Relations: http://www.cosmopharma.com/investors
Phone: 35318170370
COSMO PHARMACEUTICALS NV / C43.DE FAQ
What is the stock price of COSMO PHARMACEUTICALS NV today?
The current stock price of C43.DE is 57.5 EUR. The price decreased by -3.36% in the last trading session.
What is the ticker symbol for COSMO PHARMACEUTICALS NV stock?
The exchange symbol of COSMO PHARMACEUTICALS NV is C43 and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is C43.DE stock listed?
C43.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for COSMO PHARMACEUTICALS NV stock?
10 analysts have analysed C43.DE and the average price target is 103.37 EUR. This implies a price increase of 79.77% is expected in the next year compared to the current price of 57.5. Check the COSMO PHARMACEUTICALS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is COSMO PHARMACEUTICALS NV worth?
COSMO PHARMACEUTICALS NV (C43.DE) has a market capitalization of 1.01B EUR. This makes C43.DE a Small Cap stock.
How many employees does COSMO PHARMACEUTICALS NV have?
COSMO PHARMACEUTICALS NV (C43.DE) currently has 339 employees.
What are the support and resistance levels for COSMO PHARMACEUTICALS NV (C43.DE) stock?
COSMO PHARMACEUTICALS NV (C43.DE) has a resistance level at 67.58. Check the full technical report for a detailed analysis of C43.DE support and resistance levels.
Is COSMO PHARMACEUTICALS NV (C43.DE) expected to grow?
The Revenue of COSMO PHARMACEUTICALS NV (C43.DE) is expected to grow by 61.12% in the next year. Check the estimates tab for more information on the C43.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy COSMO PHARMACEUTICALS NV (C43.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of C43.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of C43.DE, evaluating the profitability, health, valuation and growth aspects
- COSMO PHARMACEUTICALS NV (C43.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- COSMO PHARMACEUTICALS NV (C43.DE) Sales and EPS estimates to see what analysts future expectations are.
- COSMO PHARMACEUTICALS NV (C43.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- COSMO PHARMACEUTICALS NV (C43.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- COSMO PHARMACEUTICALS NV (C43.DE) Stock Chart to make your own analysis
- COSMO PHARMACEUTICALS NV (C43.DE) Latest news and press-releases to stay up to date.
Does COSMO PHARMACEUTICALS NV (C43.DE) stock pay dividends?
COSMO PHARMACEUTICALS NV (C43.DE) has a dividend yield of 3.47%. The yearly dividend amount is currently 1.06. Check the full fundamental report for a detailed analysis of C43.DE dividend history, reliability and sustainability.
What is the Price/Earnings (PE) ratio of COSMO PHARMACEUTICALS NV (C43.DE)?
The PE ratio for COSMO PHARMACEUTICALS NV (C43.DE) is 13.31. This is based on the reported non-GAAP earnings per share of 4.32 and the current share price of 57.5 EUR. Check the full fundamental report for a full analysis of the valuation metrics for C43.DE.
C43.DE Technical Analysis
C43.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to C43.DE. C43.DE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
C43.DE Financial Highlights
Over the last trailing twelve months C43.DE reported a non-GAAP Earnings per Share(EPS) of 4.32. The EPS increased by 549.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 37.53% | ||
| ROA | 10.9% | ||
| ROE | 13.96% | ||
| Debt/Equity | 0 |
C43.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to C43.DE. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 76.44% and a revenue growth 61.12% for C43.DE